To amend the Public Health Service Act with respect to the Living Organ Donation Reimbursement Program.

The 'Expanding Support for Living Donors Act of 2026' (H.R. 7868) directly amends Section 377 of the Public Health Service Act to expand eligibility for the Living Organ Donation Reimbursement Program by removing income limits for individuals with household incomes at or below 700 percent of the poverty line. Crucially, it establishes a maximum reimbursement amount of $10,000 for fiscal year 2027, adjusted annually for inflation. This legislative action directly increases the financial viability for individuals to become living organ donors, which will increase the supply of organs available for transplant. This increased supply will directly translate into a higher volume of transplant surgeries and associated medical services. The money trail for this bill flows directly through grant recipients under the Public Health Service Act, who will reimburse donating individuals. The increased reimbursement caps and expanded eligibility will incentivize more individuals to donate, leading to a higher demand for transplant-related medical services. Companies involved in transplant diagnostics, surgical equipment, immunosuppressants, and post-operative care will see increased revenue. This includes diagnostic companies like LabCorp ($LH) and Quest Diagnostics ($DGX), medical device manufacturers such as Medtronic ($MDT) and Stryker ($SYK), and pharmaceutical companies producing immunosuppressants, like Johnson & Johnson ($JNJ). Historically, legislative actions that increase access to healthcare services or expand reimbursement for specific procedures have led to direct market gains for relevant healthcare providers and manufacturers. For example, the Affordable Care Act (ACA) in 2010, while broader in scope, expanded insurance coverage and increased demand for medical services, leading to sustained growth in the healthcare sector. While not directly comparable in scale, the mechanism of increased reimbursement driving service utilization is consistent. Specific data for organ donation reimbursement changes are scarce, but any expansion of covered services or increased financial incentives for patients/donors directly correlates with increased procedure volumes. Specific winners include companies providing diagnostic services for donor and recipient matching, such as LabCorp ($LH) and Quest Diagnostics ($DGX). Medical device companies like Medtronic ($MDT) and Stryker ($SYK), which supply surgical instruments and equipment for transplant procedures, will benefit from increased surgical volumes. Pharmaceutical companies, including Johnson & Johnson ($JNJ), which produce immunosuppressant drugs essential for post-transplant care, will also see increased demand. Telehealth providers like Teladoc Health ($TDOC) may also see increased demand for pre- and post-operative consultations, particularly in rural areas. There are no direct losers from this bill; its impact is purely additive to the healthcare market. This bill was introduced on March 9, 2026, and referred to the Committee on Energy and Commerce and the Committee on Ways and Means. The sponsorship by Rep. DelBene (D-WA), a senior member, indicates moderate legislative momentum. The next steps involve committee review and potential markups. If passed, the increased reimbursement amounts would take effect for fiscal year 2027, meaning companies should anticipate increased procedure volumes and associated revenue streams starting in late 2026 or early 2027.